Neurotoxicity characterization phase II randomized study of nab-paclitaxel versus conventional paclitaxel as first-line therapy of metastatic HER2-negative breast cancer. [Ensayo fase II randomizado para la caracterización de la neurotoxicidad de nab-paclitaxel versus paclitaxel convencional en primera línea de cáncer de mama metastásico HER2-negativo.]
Phase of Trial: Phase II
Latest Information Update: 09 May 2016
At a glance
- Drugs Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 28 Mar 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 07 May 2015 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.